FDA Opens a New Systemic Option for Tenosynovial Giant Cell Tumor
The FDA has approved Pimjetmi, Merck KGaA’s once-daily pimicotinib, for adults with tenosynovial giant cell tumor when surgery could damage joint function or create severe complications. For a disease centered in joints and surrounding tissue, that is a meaningful shift. It gives clinicians a systemic treatment choice for patients who may be poor surgical candidates or for whom repeated operations would only deepen disability.
TGCT is unusual in oncology because it is not classified as cancer; the tumors do not spread. Yet the clinical burden can be substantial. These growths can be painful, disfiguring, and mechanically destructive, limiting range of motion and daily function even before they are removed. Recurrence after surgery remains part of the disease burden, and operative management itself carries complication risk. In practical terms, a tumor that does not metastasize can still behave like a chronic orthopedic and inflammatory problem that repeatedly erodes mobility.
Pimjetmi enters a narrow market, but the setting is consequential. Adults with TGCT have effectively had only two prior small-molecule CSF-1 pathway therapies, and the new approval adds another oral option to a space defined by high unmet need and long treatment horizons.
CSF-1 Biology Sits at the Center of the Approval
The therapeutic logic behind pimicotinib is straightforward and biologically coherent. TGCT stems from a genetic abnormality that drives overexpression of colony-stimulating factor 1, or CSF-1, a protein that attracts cells supporting tumor growth. Pimjetmi blocks the CSF-1 receptor, interrupting the signaling axis that sustains the cellular milieu inside the lesion. In a tumor driven less by classic malignant spread than by a self-reinforcing inflammatory and proliferative environment, receptor blockade is an intuitive way to reduce the mass effect and the symptom burden.
The approved drug will be marketed as a once-daily pill, a formulation advantage that may matter in a chronic rare tumor where adherence and convenience often shape real-world use as much as efficacy does. Daily oral dosing also distinguishes the regimen from some competing therapies, though efficacy and safety will ultimately determine how prescribers position it.
A single sentence captures the regulatory significance: TGCT now has another FDA-approved systemic therapy built around the same biologic dependency that drives the disease.
Phase 3 Data Showed Tumor Responses and Symptom Gains
The approval rested on Phase 3 results at 25 weeks. In that study, Pimjetmi produced a 56% overall response rate, compared with 3% in the placebo group. That level of separation is difficult to dismiss in a rare tumor trial, especially when the comparator arm stayed near the floor. The magnitude of benefit suggests the drug is acting on the core disease driver rather than producing marginal symptom relief alone.
Secondary outcomes also moved in clinically meaningful directions. Range of motion, physical function, and pain improved, and the improvements were reported as both clinically meaningful and statistically significant. Those endpoints matter because TGCT is not judged only by radiographic shrinkage or response rates. Patients live with stiffness, restricted movement, discomfort, and the threat of losing function in an already compromised joint. A treatment that reduces the tumor while improving movement and pain speaks directly to the everyday burden of the disease.
The detailed data were presented at the 2025 annual meeting of the American Society of Clinical Oncology, placing the study in the established oncology evidence pathway even though TGCT itself is not a metastatic malignancy. The trial data also helped frame the current approval around a concrete, measurable benefit rather than a theoretical mechanism.
Safety Positioning Will Shape How the Drug Is Used
Merck has said the drug was well tolerated in the pivotal trial, with no evidence of liver toxicity. That finding matters because liver safety has been a defining concern in this therapeutic class. Daiichi Sankyo’s Turalio, the first FDA-approved TGCT drug, carries a black box warning for liver toxicity, a label feature that has complicated its use and blocked marketing authorization in Europe. Ono Pharmaceuticals’ Romvimza, another TGCT therapy, does not carry a black box warning, though its label advises against use in patients with elevated liver enzymes because of potential hepatic risk.
Merck’s label includes a similar precaution, but the absence of observed liver toxicity in the pivotal study gives Pimjetmi a potentially important differentiator. If that profile holds up in broader use, prescribers may view it as a more comfortable oral option for patients who need chronic treatment and careful tolerability management. The absence of a strong liver signal does not erase the need for monitoring, but it may widen the practical margin for use in a disease where alternatives are limited and surgery is not always feasible.
The competitive setting is now more crowded than it was a few years ago, but the bar remains the same: preserve function, reduce pain, and avoid creating a new toxicity burden in patients already living with a chronic joint disorder.
Merck KGaA Is Building a Rare Tumor Franchise
Pimjetmi is also part of a larger corporate strategy. Merck KGaA has been assembling a rare tumor portfolio through a series of deals, and the TGCT approval fits that broader pattern. The drug was initially developed by Abbisko Therapeutics in Shanghai. Merck secured commercialization rights in Greater China in 2023 and later paid $85 million to exercise an option for rights in the rest of the world.
The company has also moved aggressively on adjacent assets. It paid $3.9 billion to acquire SpringWorks Therapeutics, which already had two FDA-approved therapies for rare tumors, and it recently struck a $1.1 billion deal to buy Silence Therapeutics, whose lead asset is a small interfering RNA therapy being tested in polycythemia vera, a rare blood cancer. Those transactions show a deliberate investment thesis: rare tumors may not be large markets, but they can support durable franchises when the biology is clear and the clinical need is sustained.
Pimicotinib first received approval for TGCT in China late last year, and the drug has since gained approvals in Canada and Switzerland. It remains under regulatory review in Europe. For patients with TGCT, the practical question is no longer whether CSF-1 inhibition works. The more immediate question is how each approved option will be used across different safety profiles, dosing schedules, and patient needs, especially in those trying to avoid surgery or recover function after it has already been lost.